MaMR: Cloud-based Mortality & Morbidity Review SaaS for use across all NHS providers

MaMR：基于云的死亡率

• 批准号: 104553
• 金额: $ 29.69万
• 依托单位: MEANTIME INFORMATION TECHNOLOGIES LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2018
• 资助国家: 英国
• 起止时间: 2018 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=104553
• 关键词: MaMR; Cloud; based; Mortality; Morbidity

"Meantime's AMaT is already licensed to two NHS Foundation Acute Trusts (~8000 users), has been identified as a product of interest by NHS Improvement and the Innovation Agency (NorthWest) and has a growing sales pipeline because, in the words of Steve O'Brien, Associate Director Quality, Lancashire Teaching Hospitals Trust _""_AMaT is intuitive and perfectly aligned with our processes. Our clinical colleagues are queuing up to use it.""Building from this work, and drawing on Meantime's user- and team-centred software design principles, the consortium will develop MaMR, a novel SaaS for patient data analysis and action tracking enabling dozens of users, teams, specialities, departments and Trusts to learn from whole patient pathway data, many weeks quicker than existing solutions. The teams' primary challenge is the realisation of solutions that overcome significant technical uncertainties around* Analyzing, defining and systematizing diverse and complex multi-interdisciplinary NHS team workflows while closely following the Royal College of Physicians Structured Judgement Review Method (RCP SJR)* Maintaining a simple interface. Losing user take-up at any stage is unacceptable, and would defeat the objective.* Managing patient data sharing permissions across NHS teams, specialities and Trusts* Integrations with other reporting and information systems (MEDICU, Datex, QuadraMed)* Real-time patient data input and review sharing across many thousands of usersThere is nothing on the market combining morbidity and mortality data storage, analysis, and management solutions capable of powering an entire pipeline of analysis.The MaMR prototype will provide transparency within NHS Provider organisations in the form of dashboards and reports, addressing need and allowing organisations and their wider health economy to access timely reviews and embark on the improvement projects that are necessary to bring about change and better patient outcomes."

“与此同时，AMaT已经授权给两个NHS基金会急性信托（约8000名用户），已被确定为NHS改进和创新机构（西北）感兴趣的产品，并有一个不断增长的销售渠道，因为，用史蒂夫奥布莱恩的话，副主任质量，兰开夏教学医院信托_"AMaT是直观的，完全符合我们的流程。我们的临床同事正在排队使用它。“在这项工作的基础上，并借鉴Meantime以用户和团队为中心的软件设计原则，该联盟将开发MaMR，这是一种用于患者数据分析和行动跟踪的新型SaaS，使数十名用户，团队，专业，部门和信托能够从整个患者路径数据中学习，比现有解决方案快了许多周。团队的主要挑战是实现解决方案，克服围绕 * 分析，定义和系统化多样化和复杂的多学科NHS团队工作流程的重大技术不确定性，同时密切关注皇家医师学院结构化判断审查方法（RCP SJR）* 保持一个简单的界面。在任何阶段失去用户使用都是不可接受的，并且会破坏目标。管理NHS团队、专业和信托机构之间的患者数据共享权限 * 与其他报告和信息系统集成（MEDICU，Datex，QuadraMed）* 实时患者数据输入和成千上万用户的审查共享市场上没有任何产品将发病率和死亡率数据存储，分析，和管理解决方案，能够为整个分析管道提供动力。MaMR原型将以仪表板和报告的形式在NHS提供商组织内提供透明度，满足需求，允许组织及其更广泛的卫生经济获得及时的审查，并着手进行必要的改进项目，以实现变革和更好的患者结果。"